key: cord-0762841-zi35k4d0
authors: Masson Regnault, Marie; Shourick, Jason; Jendoubi, Fatma; Tauber, Marie; Paul, Carle
title: Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review
date: 2022-04-30
journal: Am J Clin Dermatol
DOI: 10.1007/s40257-022-00679-y
sha: 9ae6a6e6f1b7a429ba289554a1a02977884aee92
doc_id: 762841
cord_uid: zi35k4d0

BACKGROUND: The decision of when to discontinue systemic treatment after achieving remission in psoriasis is an important question. In this systematic review, we sought to evaluate time to relapse after the discontinuation of systemic treatment in psoriasis patients. METHODS: Systematic searches of PubMed, Cochrane Library, and Embase databases were performed for randomized controlled studies reporting time to relapse after discontinuation of systemic drugs in psoriasis patients. In addition, pharmaceutical companies were contacted by the authors regarding missing data from the identified publications. In each publication, the time to psoriasis relapse and the timing of drug discontinuation were carefully assessed. The level of psoriasis control at the time of drug discontinuation and the definition used for psoriasis relapse were taken into account. RESULTS: Thirty articles published before April 2021 were included in the systematic review. Four articles focused on conventional systemic treatments with methotrexate and/or cyclosporine, nine focused on tumor necrosis factor (TNF) antagonists, eight focused on interleukin-17 (IL-17) antagonists, eight focused on IL-12/23 or IL-23 antagonists, and one focused on tofacitinib and apremilast. Different definitions were used to define psoriasis treatment success at the time of drug discontinuation. Similarly, heterogeneous criteria were used to define psoriasis relapse. Comparison between drugs was performed indirectly (i.e. across studies) for most drugs. Considering time of 50% loss of maximum Psoriasis Area Severity Index (PASI) improvement, a shorter median time to psoriasis relapse was observed with traditional systemic treatment (~ 4 weeks) compared to biological agents (from 12 to ~ 34 weeks). When using stringent relapse criteria, such as loss of PASI 90, a longer time to relapse after treatment cessation was observed with IL-23 antagonists (21–42 weeks) versus IL-17 antagonists (7–24 weeks). CONCLUSION: Biological agents are associated with a longer time to relapse than oral systemic agents after drug discontinuation. Among biologicals, IL-23 antagonists are associated with the longest time to relapse. These findings may have clinical consequences for the selection of systemic agents when intermittent treatment is necessary. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40257-022-00679-y.

Biologics for psoriasis generally promote excellent disease control [1] [2] [3] . Recent practical data from experienced centers and international registries have shown both sustained treatment benefits and fairly good long-term safety with no major increase in serious infections, cancer, or mortality after more than 5 years of treatment [4] [5] [6] .

Although discontinuation of biologics is associated with a risk of relapse, it may be advisable for several reasons, including a desire expressed by patients to reduce the treatment burden, treatment costs that cannot be covered, the occurrence of adverse events, and specific circumstances such as pregnancy. Time to relapse following treatment discontinuation appears to be very short with some therapeutic agents [7] . Most registration programs for new dermatology drugs include studies with a treatment withdrawal period to assess the potential for rebound effects and to determine the time to psoriasis relapse. The treatment withdrawal period can also be used to assess the effectiveness of treatment reintroduction.

The analysis of the dynamics of psoriasis relapse during the treatment withdrawal period provides relevant information regarding the potential usage of the drug in the clinic.

This systematic review aims to estimate the psoriasis relapse time after systemic drug discontinuation in psoriasis.

The systematic review was prospectively registered at the PROSPERO register under number CRD42021252182.

We included randomized controlled trial studies that investigated the time to relapse following discontinuation of systemic treatment with fumarates, acitretin, methotrexate, cyclosporine, infliximab, etanercept, adalimumab, certolizumab pegol, ustekinumab, secukinumab, ixekizumab, brodalumab, bimekizumab, guselkumab, tildrakizumab, risankizumab, tofacitinib, or apremilast in patients with plaque psoriasis.

For the literature search, we have used the recent Cochrane skin group systematic review from November 2019 [1] . From the 140 studies included, we selected those that included a withdrawal period. A supplementary literature search from the earliest available date to April 2021 was performed in the PubMed, Cochrane Library, and Embase databases using the keywords ("Psoriasis" [Mesh] OR "Plaque psoriasis"[tiab]) AND ("Fumarates" [Mesh] OR "acid fumaric" [tiab] OR "Acitretin" [Mesh] OR "Acitretin" [tiab] OR "Methotrexate" [Mesh] OR "Methotrexate" [tiab] OR "Cyclosporine" [Mesh] OR "Cyclosporine" [tiab] OR "Ciclosporine" [tiab] OR "Inf liximab" [Mesh] OR "Infliximab" [ ) (see the "Supplementary Information" in the electronic supplementary material). The reference lists of included articles were also screened manually for additional studies. Moreover, we contacted individual pharmaceutical companies to provide data missing from the published studies on the time of relapse post-drug withdrawal.

The authors (Marie Masson Regnault, Jason Shourick, and Carle Paul) independently searched the databases for potentially relevant article titles and abstracts based on the inclusion criteria. Full text articles were then retrieved. We used the modified Cochrane Collaboration tool to assess risk of bias for randomized controlled trials. Bias was assessed as a judgment (high, low, or unclear) for individual elements from five domains (selection, performance, detection, attrition, and reporting bias) (see the "Supplementary Information" in the electronic supplementary material). The authors were independently involved in all stages of study selection and data extraction in terms of the number of patients enrolled in all of the studies, the number of patients in the withdrawal period, the criteria used for treatment withdrawal, the criteria defining relapse, post-withdrawal followup time, and the time to relapse.

Overall, 30 original articles published before April 2021 were included in this review, but several papers report on the same study. Thus, we included 25 studies that report on 27 drug data points about time to relapse (Fig. 1) . They are presented in Table 1 . No randomized controlled trial was found investigating time to relapse with fumarates or acitretin. Four studies focused on conventional systemic treatments with methotrexate and/or cyclosporine [8] [9] [10] [11] , nine focused on tumor necrosis factor (TNF) antagonists [12] [13] [14] [15] [16] [17] [18] [19] [20] , six focused on interleukin-17 (IL-17) antagonists [21] [22] [23] [24] [25] [26] [27] 37] , six focused on IL-12/23 or IL-23 antagonists [15, [28] [29] [30] [31] [32] [33] [34] , and one study each focused on tofacitinib [35] and apremilast [36] . The number of patients enrolled in these withdrawal-period studies varied from 14 

The therapeutic success criteria determining inclusion of patients in the withdrawal period varied across studies. In three studies, patients had to attain Psoriasis Area Severity Index (PASI) 50 [12] or Physician's Global Assessment (PGA) ≤ 2 [13, 14] . Patients had to achieve PASI 75 (± PGA 0-1), PASI 90 (± PGA 0-1), or only PGA 0-1 in 15 [8, 11, 15, 16, 18, 20-23, 26, 28, 30, 32, 35, 36] , four [9, 24, 33, 37] , and three studies [10, 17, 29] , respectively. The therapeutic success criteria became more stringent in recent studies. Indeed, the achievement of PASI 90 or PGA 0-1 was used as a primary end point for the first time with the ixekizumab study published by Gordon et al. in 2016 and thereafter for the brodalumab, guselkumab, risankizumab, and bimekizumab studies [24] . The onset of the withdrawal period varied from 4 to 40 weeks after the beginning of treatment.

Similarly, heterogenous criteria were used across different studies to define psoriasis relapse. Relapse was sometimes defined by multiple criteria in the same study ( Table 1 ). The definition of relapse became more stringent in the most recent studies evaluating biological agents. The duration of follow-up after treatment discontinuation varied from 8 to 108 weeks [mean 33.1 ± 21.58median 30 (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) ]. 

Given the variability in the relapse evaluation criteria, we have computed the time to relapse for each molecule under consideration, ranging from the longest to the shortest time to relapse (Fig. 2a, b) . In most cases, the comparison between drugs was indirect. The time to loss of PASI 75 was compared between etanercept and ustekinumab in one study [15] . 

For patients treated with oral cyclosporine, four studies evaluated time to relapse in 25, 14, 20, and 192 patients, respectively [8] [9] [10] [11] . Each study used a different relapse definition. Relapse was defined as the moment when patients felt a new course of cyclosporine was required, as a 2-point reduction in a 7-point severity scale, or as a 50% loss of maximum PASI improvement. The median length of time to the perceived need for a new course of cyclosporine treatment varied from 9.5 to 16 weeks. The median time to loss of 50% of maximum PASI improvement was about 4 weeks. For methotrexate patients in a small study (n = 17), relapse was defined as a 50% loss of maximum PASI improvement or when the patients felt treatment was needed [9] . Similarly to cyclosporine, the median time to loss of 50% of maximum PASI improvement was 4 weeks (Fig. 2a) .

Four studies focused on etanercept [12] [13] [14] [15] , two studies each focused on adalimumab [16, 17] and infliximab [18, 19] , and one study focused on certolizumab pegol [20] . [13-15, 17, 18] , an increase of more than 6 points in the PASI score in one study [16] , a loss of PASI 50 in two studies [12, 16] , a 50% reduction in maximum PASI response in two studies [12, 20] , and a loss of PASI 75 in three studies [12, 18, 19] (Fig. 2a) .

Three studies were identified for secukinumab [21] [22] [23] , two for ixekizumab [24, 25] , two for brodalumab [26, 27] , and one for bimekizumab [37] . The number of patients included varied from 67 to 423 patients [mean 171.6 ± 134.1; median 132 (84-188.5)]. The time to relapse was reported as a loss of PGA ≤ 2 in four studies [24] [25] [26] [27] , a one-third loss of maximum PASI improvement in one study [21] , a loss of 50% of maximum PASI improvement in one study [23] , a loss of PASI 75 for three studies [22, 24, 25, 37] , a loss of PASI 90 in four studies [23, 24, 26, 37] , a loss of PASI 100 in three studies [24, 26, 37] , and a loss of PGA 0-1 in one study [26] . The median time to loss of PGA ≤ 2 was about 20 weeks for ixekizumab and 9 weeks for brodalumab. The median time to loss of PASI 75 varied from 20 to 24 weeks for secukinumab 300 mg. It was about 20 weeks for ixekizumab and estimated at 32 weeks for bimekizumab. The median time to loss of PGA 0-1 for brodalumab was estimated to be between 6 and 7 weeks. For brodalumab, ixekizumab, secukinumab 300 mg, and bimekizumab, the median time to loss of PASI 90 was estimated to be 7 weeks, 16 weeks, 16 weeks, and 24 weeks, respectively. For brodalumab, ixekizumab, and bimekizumab, the median time to loss of PASI 100 was estimated to be 6 weeks, 12 weeks, and 18 weeks, respectively (Fig. 2a, b) .

We included two studies for ustekinumab [15, 28] , two for guselkumab [33, 34] , one for risankizumab [29] , and three for tildrakizumab [30] [31] [32] . The number of patients included in the withdrawal period ranged from 113 to 399 [mean 243.2 ± 105.8; median 229 (176. ]. Time to relapse was reported as a loss of 50% maximum PASI improvement in nine studies [9, 12, 20, 23, 28, [30] [31] [32] [33] [34] [35] , a loss of PASI 75 in five studies [28, [30] [31] [32] [33] , a loss of PASI 90 in six studies [28, 29, [31] [32] [33] [34] , a loss of PGA 0-1 in three studies [26, 27, [29] [30] [31] , and a loss of PASI 100 in two studies [29, 33] . The median time to loss of PASI 75 was about 15 weeks for ustekinumab compared to over 28 weeks for guselkumab and about 32.3 for tildrakizumab (100 mg). The median time to loss of PASI 90 was estimated at 20 weeks for ustekinumab, between 23 and 24 weeks for guselkumab, 27.9 weeks for tildrakizumab (100 mg), and 42 weeks for risankizumab. The median time to loss of PGA 0-1 was estimated to be 28 weeks for guselkumab, 28 weeks for tildrakizumab (100 mg), and 44 weeks for risankizumab (Fig. 2a, b) .

We found one tofacitinib study including 291 patients in the withdrawal period [35] . Patients who obtained PASI 75 and PGA 0-1 responses were selected to enter the withdrawal period. The relapse was defined as a 50% loss in maximum PASI improvement during initial treatment or a loss of a PASI 75 response. Median time to a 50% loss of maximum PASI response was 16.1 weeks. Median time to a loss of PASI 75 response was 8 weeks (Fig. 2a) . We found one study for apremilast [36] . The relapse was defined as a loss of PASI 75. The median time to initial loss of PASI 75 after re-randomization at week 32 was 5.1 weeks (95% confidence interval 4.1-8.1) (Fig. 2a) .

The mean terminal elimination half-life of different drugs was collected from product information or public assessment reports available on the European Medicines Agency's (EMA) website. These are presented from the longest to the shortest maintenance response we determined in the previous subsection (Fig. 3 ).

Systemic treatment is used as induction and maintenance therapy in patients with moderate to severe psoriasis. In a real-life setting, discontinuation of treatment may be triggered by life events such as pregnancy or concomitant disease. It may also be motivated by a patient's desire to have drug-free intervals or to reduce the treatment burden. Based on indirect comparison, overall, we noted a longer period of maintained response after discontinuation of biological agents as compared with oral systemic treatment. Moreover, treatment with IL-12/23 and IL-23 antagonists showed a tendency for a longer time to relapse compared to IL-17 and TNF antagonists. It should be noted that due to clinical trial constraints, the drug discontinuation was performed relatively early. It remains to be determined whether discontinuation after a long period in remission would produce the same results. Future studies are needed to investigate whether drug discontinuation after sustained complete remission of psoriasis can be associated with long-term psoriasis clearance in some patients. The time to relapse after treatment discontinuation is particularly interesting in clinical settings where the use of systemic agents may be detrimental. A recent example is the worldwide coronavirus disease 2019 (COVID-19) pandemic, during which practitioners were initially concerned about maintaining treatment for patients until reassuring data were published [38] . In 2010, Kamaria et al. produced a non-systematic review comparing biologics and their respective times to relapse [39] . They showed that alefacept offered the longest clinical benefit, followed by ustekinumab, infliximab, adalimumab, etanercept, and lastly, efalizumab. More recently, Wang et al. reported a short non-systematic review on time to relapse after biologic treatment withdrawal including observational studies. They suggested that IL-23 inhibitors are associated with a longer time to relapse after treatment withdrawal than TNF inhibitors [40] .

Observational studies provide additional information about real-life psoriasis relapse following the discontinuation of biologic agents in psoriasis. Bellinato [44] . In an 8-year multicenter retrospective study, Chiu et al. reported in 202 patients responding to ustekinumab a median time to relapse (loss of 50% of the PASI maximum improvement) of 6.7 ± 4.1 months. Possible clinical predictors for longer relapse times were being biologic-naive, having a shorter psoriasis duration, absence of arthritis or chronic kidney disease, absence of family history of psoriasis, and higher and more rapid response to treatment [45] . Rivera et al. reported a median time to relapse of 282 days in patients treated with guselkumab [44] . The conclusions about these findings are limited by the very large and variable definitions used for defining relapse. Down-titration and discontinuation strategies of a biological treatment are also a topic of research in other inflammatory diseases, such as rheumatoid arthritis. It has been shown that fixed-dose reduction of TNF inhibitors is associated with maintenance of efficacy, whereas drug withdrawal leads to disease relapse [46] . One important factor to consider when evaluating continued drug effects after treatment discontinuation is the persistence of the drug in the body. Based on pharmacokinetic data, maintained response following drug discontinuation appears to partially correlate with the mean drug half-lives. Overall, the longest time to relapse was recorded with drugs with the longest half-lives. The difference in efficacy maintenance between drugs cannot be solely explained by drug half-lives. Other factors may play a role, such as molecular target and site of action in the psoriasis inflammation cascade.

The main study limitation is the scarcity of published data currently available on clinical study withdrawal periods and the considerable variability in the criteria used to define optimal clinical response before treatment discontinuation and relapse during the withdrawal period. Relapse after the discontinuation of oral systemic agents and TNF antagonists have mostly been evaluated using less-stringent measures. Only limited data were available for traditional systemic treatments such as methotrexate and cyclosporine, and no data exists for acitretin or fumarates. A consensus approach to the definition of psoriasis relapse in the treatment withdrawal period of clinical studies is needed, taking both patient and physician perspectives into account. The absence of access to individual patient data does not allow assessment of the role of demographic factors [e.g., body mass index (BMI), age, sex] or clinical variables such as baseline disease severity or age of onset of psoriasis. The effects of discontinuation of systemic therapy in psoriasis patients are unclear. In the case of molecules with long-term efficacy after discontinuation, evidence suggests that it may be possible to increase the interval between doses in some patients for IL-23 antagonists. Further high-quality research is needed in this area, with particular emphasis on doubleblind comparative randomized controlled trials in which biologic therapy or immunosuppressants are withdrawn, as well as registry data on the real-life efficacy and safety of biologic discontinuation in patients.

The data from this systematic review suggest that biological agents are associated with improved maintenance of the effect and longer time to relapse compared to oral systemic agents. Among biologicals and when considering the most stringent criteria, it seems that IL-23 antagonists are associated with a longer time to relapse post-withdrawal compared to other psoriasis treatments. These findings may have clinical consequences on the selection of systemic agents in certain situations. Indeed, when the need for systemic treatment discontinuation can be anticipated, such as for scheduled surgery, planned pregnancy, or long-term travel to countries with limited access to healthcare resources, IL-23 antagonists may be preferred based on their persistent effect.

The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s40257-022-00679-y.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis

Psoriasis pathogenesis and the development of novel targeted immune therapies

Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest

Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis

Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry

Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients

Low-dose, short-term ciclosporin (Neoral ® ) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis

Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy

Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study The PISCES Study Group

Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy

A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis

Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept

ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, doubleblind, placebo-controlled, phase II regimen-finding study

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE)

Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis

UNCOVER-1 Study Group, UNCOVER-2 Study Group, UNCOVER-3 Study Group. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase

PHOENIX 1 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies

Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial

Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1. J Eur Acad Dermatol Venereol

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo-and active comparator-controlled VOYAGE 2 trial

Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Should biologics for psoriasis be interrupted in the era of COVID-19?

How long does the benefit of biologics last? An update on time to relapse and potential for rebound of biologic agents for psoriasis

Time to relapse after treatment withdrawal for different biologics used to treat plaque psoriasis

Relapse of psoriasis in patients who asked to discontinue etanercept after achieving a stable clinical remission

Efficacy and safety of infliximab in long-term treatment of plaque-type psoriasis: a comparative retrospective study on two different (continuous vs. relapse related) regimens P2765

Drug survival rates in patients with psoriasis after treatment with biologics

Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study

Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: an eight-year multicenter study

Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity-PubMed

The authors wish to thank Maria Jazra (Janssen), Coraline Bellagarde (Novartis), Volker Koscielny (Almirall), Gaia Gallo (Lilly), and Philippe Kauffmann and Anouk Vaslet de Fontaubert (AbbVie) for providing missing data from some publications.